Cargando…

Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries

INTRODUCTION: The current use of lipid lowering therapies and the eligibility for proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors of patients surviving a myocardial infarction (MI) is poorly known. METHODS: Using the data from two contemporary, nationwide, prospective, real-world registr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colivicchi, Furio, Massimo Gulizia, Michele, Arca, Marcello, Luigi Temporelli, Pier, Gonzini, Lucio, Venturelli, Vanessa, Morici, Nuccia, Indolfi, Ciro, Gabrielli, Domenico, De Luca, Leonardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961602/ https://www.ncbi.nlm.nih.gov/pubmed/31969932 http://dx.doi.org/10.1155/2020/3856242

Ejemplares similares

Clinical Impact and Prognostic Role of Triglyceride to High-Density Lipoprotein Cholesterol Ratio in Patients With Chronic Coronary Syndromes at Very High Risk: Insights From the START Study
por: De Luca, Leonardo, et al.
Publicado: (2022)

Association of Hypertriglyceridemia with All‐Cause Mortality and Atherosclerotic Cardiovascular Events in a Low‐Risk Italian Population: The TG‐REAL Retrospective Cohort Analysis
por: Arca, Marcello, et al.
Publicado: (2020)

ANMCO Position Paper: diagnostic–therapeutic pathway in patients with hypercholesterolaemia and statin intolerance
por: Gulizia, Michele Massimo, et al.
Publicado: (2017)

ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes
por: Colivicchi, Furio, et al.
Publicado: (2017)

Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study
por: De Luca, Leonardo, et al.
Publicado: (2018)

Revascularization and Left Ventricular Dysfunction for ICD Eligibility
por: Romano, Letizia Rosa, et al.
Publicado: (2023)

Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
por: Temporelli, Pier Luigi, et al.
Publicado: (2021)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

Type of hospitalisations and in-hospital outcomes in the Italian coronary care unit network at the time of COVID-19 pandemic: the BLITZ-COVID19 Registry
por: Gulizia, Michele Massimo, et al.
Publicado: (2022)

Reply to Kielb et al. Untapped Potential for Female Patients? Comment on “Lucà et al. Update on Management of Cardiovascular Diseases in Women. J. Clin. Med. 2022, 11, 1176”
por: Lucà, Fabiana, et al.
Publicado: (2022)

The Outbreak of COVID-19 in Italy: Fighting the Pandemic
por: Indolfi, Ciro, et al.
Publicado: (2020)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Impact of Working from Home on Cardiovascular Health: An Emerging Issue with the COVID-19 Pandemic
por: Di Fusco, Stefania Angela, et al.
Publicado: (2021)

Italian Association of Hospital Cardiologists practical guidance for sodium–glucose cotransporter 2 inhibitors use in patients with heart failure
por: Di Fusco, Stefania Angela, et al.
Publicado: (2023)

Contemporary Trends and Age‐Specific Sex Differences in Management and Outcome for Patients With ST‐Segment Elevation Myocardial Infarction
por: De Luca, Leonardo, et al.
Publicado: (2016)

How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post‐MI Study
por: De Luca, Leonardo, et al.
Publicado: (2019)

Screening and management of dyslipidemia in oncologic patients undergoing cardiotoxic therapies: results from an Italian survey
por: Camilli, Massimiliano, et al.
Publicado: (2023)

Incidence, Characteristics, and Management of Patients with Recurrent Myocardial Infarctions: Insights from the EYESHOT POST-MI
por: De Luca, Leonardo, et al.
Publicado: (2022)

Home-based COVID 19 management: A consensus document from Italian general medical practitioners and hospital consultants in the Lombardy region (Italy)
por: Morici, Nuccia, et al.
Publicado: (2021)

Risk stratification vs routine intensive care stay in non ST segment elevation myocardial infarction (NSTEMI)
por: Savonitto, Stefano, et al.
Publicado: (2020)

Mechanical circulatory support in CS: device or patient?
por: Morici, Nuccia, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries
por: Olimpieri, P.P., et al.
Publicado: (2020)

Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care
por: Colivicchi, Furio, et al.
Publicado: (2016)

ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy
por: Riccio, Carmine, et al.
Publicado: (2017)

ANMCO position paper: 2022 focused update of appropriate use criteria for multimodality imaging: aortic valve disease
por: Nardi, Federico, et al.
Publicado: (2022)

ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure
por: Di Tano, Giuseppe, et al.
Publicado: (2021)

Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence
por: Condello, Francesco, et al.
Publicado: (2023)

Lead failure in transvenous implantable cardioverter defibrillator: a new opportunity for an effective management
por: Pignalberi, Carlo, et al.
Publicado: (2018)

COVID-19, Vaccines, and Thrombotic Events: A Narrative Review
por: Abrignani, Maurizio G., et al.
Publicado: (2022)

Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain
por: Cosin-Sales, Juan, et al.
Publicado: (2022)

Antiplatelet therapy for elderly patients with Acute Coronary Syndromes
por: Savonitto, Stefano, et al.
Publicado: (2018)

Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMEU) and Italian Society of Interventional Cardiology (SICI-GISE)
por: De Luca, Leonardo, et al.
Publicado: (2017)

Can Contemporary Patients with Biopsy Gleason Score 3+4 Be Eligible for Active Surveillance?
por: Kwon, Ohseong, et al.
Publicado: (2014)

Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
por: Shen, Miles, et al.
Publicado: (2022)

ANMCO-SIMEU consensus document: appropriate management of atrial fibrillation in the emergency department
por: Caldarola, Pasquale, et al.
Publicado: (2023)

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
por: Gronda, Edoardo G., et al.
Publicado: (2022)

Spotlight on Italian Association of Hospital Cardiologists (ANMCO) activity in the 2–year period 2021–2023
por: Di Fusco, Stefania Angela, et al.
Publicado: (2023)

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)
por: Mocini, David, et al.
Publicado: (2021)

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes
por: Gronda, Edoardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p32fk2k41jjesfco6c0gh21m6g